Diabetic cardiomyopathy in a young patient
Authors:
Company:
1 Botkin City Clinical Hospital, Moscow, Russian Federation
2 Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation
3 First Sechenov Moscow State Medical University, Moscow, Russian Federation
For correspondence: Sign in or register.
Type: Clinical Cases
DOI:
For citation: Ametov A.S., Pashkova E.Yu., Vengerova E.N., Bairova V.E., Bedina A.V. Diabetic cardiomyopathy in a young patient. Creative Cardiology. 2024; 18 (4): 523–530 (in Russ.). DOI: 10.24022/1997-3187-2024-18-4-523-530
Received / Accepted: 25.10.2024 / 29.11.2024
Keywords: diabetic cardiomyopathy complications of diabetes mellitus sodium-glucose cotransporter type 2 inhibitors heart failure
Abstract
Aim – to demonstrate the outcome of long-term lack of compensation for diabetes mellitus, resulting in development of diabetic cardiomyopathy and severe heart failure, as well as proliferative retinopathy, diabetic nephropathy and distal polyneuropathy in a young patient.Diabetic cardiomyopathy is characterized by myocardial dysfunction and development of symptoms of heart failure. Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors have a beneficial effect on the course of diabetic cardiomyopathy, providing prevention of structural damage and dysfunction of cardiomyocytes. Moreover, the use of SGLT-2 inhibitors can be considered for patients with type 1 diabetes mellitus, since the benefits including cardioprotective effect prevail over the risk of developing diabetic ketoacidosis.
Diabetic cardiomyopathy is a late complication of diabetes mellitus, which not only significantly reduces the patients’ quality of life, but can also lead to disability and death. It is extremely important to educate patients, increase patient adherence to treatment and improve the accessibility and quality of medical care for patients with diabetes.
References
- Dunlay S.M., Givertz M.M., Aguilar D., Allen L.A., Chan M., Desai A.S. et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/ AHA/HFSA heart failure guideline update [published correction appears in Circulation. 2019; 140 (12): e692]. Circulation. 2019; 140 (7): e294–e324. DOI: 10.1161/CIR.0000000000000691
- Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 1972; 30 (6): 595–602. DOI: 10.1016/0002-9149(72)90595-4
- Nakamura K., Miyoshi T., Yoshida M., Akagi S., Saito Y., Ejiri K. et al. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. Int. J. Mol. Sci. 2022; 23 (7): 3587. DOI: 10.3390/ijms23073587
- Alonso N., Moliner P., Mauricio D. Pathogenesis, clinical features and treatment of diabetic cardiomyopathy. Adv. Exp. Med. Biol. 2018; 1067: 197–217. DOI: 10.1007/5584_2017_105
- Huang K., Luo X., Liao B., Li G., Feng J. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovasc. Diabetol. 2023; 22 (1): 86. DOI: 10.1186/s12933-023-01816-5
- Janssens B., Caerels S., Mathieu C. SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects. Ther. Adv. Endocrinol. Metab. 2020; 11: 2042018820938545. DOI: 10.1177/2042018820938545
- Dandona P., Mathieu C., Phillip M., Hansen L., Griffen S., Tschöpe D. et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial [published correction appears in Lancet Diabetes Endocrinol. 2017; 5 (12): e8. DOI: 10.1016/S2213-8587(17)30375-3]. Lancet Diabetes Endocrinol. 2017; 5 (11): 864–876. DOI: 10.1016/S2213-8587(17)30308-X
- Lu J., Tang L., Meng H., Zhao J., Liang Y. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials. Diabetes Metab. Res. Rev. 2019; 35 (7): e3169. DOI: 10.1002/dmrr.3169
About Authors
- Aleksandr S. Ametov, Dr. Med. Sci., Professor, Chief of Chair of Endocrinology, Chief of Network Chair, Endocrinologist; ORCID
- Evgeniya Yu. Pashkova, Cand. Med. Sci., Associate Professor of Chair, Senior Researcher, Head of Department; ORCID
- Elina N. Vengerova, Endocrinologist; ORCID
- Valeriya E. Bairova, Resident; ORCID
- Anastasiya V. Bedina, Student; ORCID
